IP Library › Granted Patent US 12,263,250
Granted Patent B2
US 12,263,250 · App. 17/044,949 · Granted Apr 1, 2025

Nanofiber segments and methods of use thereof

Inventors: Jingwei Xie (Omaha, NE); Sunil Kumar Boda (Omaha, NE)
Assignee: BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA
A61K9/1658A61K9/0024A61K9/1641A61L27/227A61L27/54A61L2400/12A61L2430/02B82Y5/00B82Y30/00B82Y40/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,263,250
App. No.
17/044,949
Granted
Apr 1, 2025
Kind
B2
Abstract

Nanofiber segments comprising polymeric electrospun nanofibers are provided as well as methods of use thereof and methods of making.

Claims (31)

1. A composition comprising nanofiber segments, wherein said nanofiber segments are electrospun nanofibers, wherein said nanofiber segments comprise a polymer, wherein said nanofiber segments have a length less than about 150 μm, and wherein said composition has a temperature less than about −20° C.

2. The composition of claim 1 , wherein said composition has a temperature less than about −80° C.

3. A composition comprising nanofiber segments, wherein said nanofiber segments are electrospun nanofibers, wherein said nanofiber segments comprise a polymer, wherein said nanofiber segments have a length less than about 150 μm, wherein said composition has a temperature less than about −20° C., and wherein said polymer comprises poly-lactic-co-glycolic acid.

4. A composition comprising nanofiber segments, wherein said nanofiber segments are electrospun nanofibers, wherein said nanofiber segments comprise a polymer, wherein said nanofiber segments have a length less than about 150 μm, wherein said composition has a temperature less than about −20° C., and wherein said polymer comprises polycaprolactone.

5. The composition of claim 1 , wherein said nanofiber segments are mineralized.

6. The composition of claim 1 , wherein said nanofiber segments are crosslinked or thermally treated.

7. The composition of claim 1 , wherein said nanofiber segments comprise cells and/or a bioactive agent.

8. The composition of claim 7 , wherein said bioactive agent is selected from the group consisting of a therapeutic agent, a growth factor, a signaling molecule, a cytokine, a hemostatic agent, an antimicrobial, and an antibiotic.

9. The composition of claim 1 , further comprising a pharmaceutically acceptable carrier.

10. The composition of claim 1 , wherein said nanofiber segments are mineralized and comprise a bone morphogenic protein or fragment of analog thereof.

11. The composition of claim 1 consisting of said nanofiber segments and a pharmaceutically acceptable carrier.

12. The composition of claim 3 , wherein said nanofiber segments are mineralized.

13. The composition of claim 3 , wherein said nanofiber segments are crosslinked or thermally treated.

14. The composition of claim 3 , wherein said nanofiber segments comprise cells and/or a bioactive agent.

15. The composition of claim 14 , wherein said bioactive agent is selected from the group consisting of a therapeutic agent, a growth factor, a signaling molecule, a cytokine, a hemostatic agent, an antimicrobial, and an antibiotic.

16. The composition of claim 3 , further comprising a pharmaceutically acceptable carrier.

17. The composition of claim 3 , wherein said nanofiber segments are mineralized and comprise a bone morphogenic protein or fragment of analog thereof.

18. The composition of claim 3 consisting of said nanofiber segments and a pharmaceutically acceptable carrier.

19. The composition of claim 4 , wherein said nanofiber segments are mineralized.

20. The composition of claim 4 , wherein said nanofiber segments are crosslinked or thermally treated.

21. The composition of claim 4 , wherein said nanofiber segments comprise cells and/or a bioactive agent.

22. The composition of claim 21 , wherein said bioactive agent is selected from the group consisting of a therapeutic agent, a growth factor, a signaling molecule, a cytokine, a hemostatic agent, an antimicrobial, and an antibiotic.

23. The composition of claim 4 , further comprising a pharmaceutically acceptable carrier.

24. The composition of claim 4 , wherein said nanofiber segments are mineralized and comprise a bone morphogenic protein or fragment of analog thereof.

25. The composition of claim 4 consisting of said nanofiber segments and a pharmaceutically acceptable carrier.

26. A method for synthesizing a nanofiber microsphere, said method comprising electrospray microdripping the composition of claim 1 into freezing conditions and isolating the synthesized nanofiber microspheres.

27. A method for synthesizing a nanofiber microsphere, said method comprising electrospray microdripping the composition of claim 3 into freezing conditions and isolating the synthesized nanofiber microspheres.

28. A method for synthesizing a nanofiber microsphere, said method comprising electrospray microdripping the composition of claim 4 into freezing conditions and isolating the synthesized nanofiber microspheres.

29. The composition of claim 1 , wherein said nanofiber segments have a length from 20 μm to 50 μm.

30. The composition of claim 3 , wherein said nanofiber segments have a length from 20 μm to 50 μm.

31. The composition of claim 4 , wherein said nanofiber segments have a length from 20 μm to 50 μm.

Assignments (2)
CONFIRMATORY LICENSE Recorded Oct 17, 2023
From: UNIVERSITY OF NEBRASKA MEDICAL CENTER
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 065257/0749 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 12, 2020
From: XIE, JINGWEI; BODA, SUNIL KUMAR
To: BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA
Reel/Frame 054346/0234 →
Continuity (3)
Provisional Application 62661171 · Apr 23, 2018
Provisional Application 62661174 · Apr 23, 2018
Related Publication 20210212949A1 · Jul 15, 2021
References Cited (29)
US 10799620B2 · Xie et al. · 2020 [cited by applicant]
US 11033659B2 · Xie et al. · 2021 [cited by applicant]
US 11318224B2 · Xie et al. · 2022 [cited by applicant]
US 11427936B2 · Xie · 2022 [cited by applicant]
US 20160015792A1 · Hendricus van Pinxteren · 2016 [cited by examiner]
US 20200164107A1 · Xie et al. · 2020 [cited by applicant]
WO 200901165A1 · 2008 [cited by examiner]
WO 2009011658A1 · 2009 [cited by examiner]
WO 2009088777A1 · 2009 [cited by applicant]
Wang et al, Dentin Regeneration by Stem Cells of Apical Papilla on Injectable Nanofibrous Microspheres and Simulated Controlled BMP-2 Release, Acta Biomaterials, vol. 36, pp. 63-72. (Year: 201). [cited by examiner]
Wang et al, Dentin Regeneration by Stem Cells of Apical Papilla on Injectable Nanofibrous Microspheres and Simulated Controlled BMP-2 Release, Acta Biomaterials, vol. 36, pp. 63-72 (Year: 2016). [cited by examiner]
Xie, et al., “Electrospray in the dripping mode for cell microencapsulation” J. Colloid Interface Sci. (2007) 312(2):247-55. [cited by applicant]
Cai, et al., “Aerogel microspheres from natural cellulose nanofibrils and their application as cell culture scaffold” Biomacromolecules (2014) 15(7):2540-7. [cited by applicant]
Wang, et al., “Dentin regeneration by stem cells of apical papilla on injectable nanofibrous microspheres and stimulated by controlled BMP-2 release” Acta Biomater. (2016) 36:63-72. [cited by applicant]
Boda, et al., “Electrospraying Electrospun Nanofiber Segments into Injectable Microspheres for Potential Cell Delivery” ACS Appl. Mater. Interfaces (2018) 10(30):25069-25079. [cited by applicant]
Boda, et al., “Mineralized nanofiber segments coupled with calcium-binding BMP-2 peptides for alveolar bone regeneration” Acta Biomater. (2019) 85:282-293. [cited by applicant]
Weng, et al., “Novel 3D Hybrid Nanofiber Aerogels Coupled with BMP-2 Peptides for Cranial Bone Regeneration” Adv. Healthcare Mater. (2018) 7:1701415. [cited by applicant]
Choi, et al., “Uniform beads with controllable pore sizes for biomedical applications” Small (2010) 6(14):1492-8. [cited by applicant]
Cai, et al., “Porous microsphere and its applications” Int. J. Nanomedicine (2013) 8:1111-20. [cited by applicant]
Liu, et al., “Nanofibrous hollow microspheres self-assembled from star-shaped polymers as injectable cell carriers for knee repair” Nat. Mater. (2011) 10(5):398-406. [cited by applicant]
Zhou, et al., “Chitosan microspheres with an extracellular matrix-mimicking nanofibrous structure as cell-carrier building blocks for bottom-up cartilage tissue engineering” Nanoscale (2016) 8(1):309-17. [cited by applicant]
Xie, et al., “Electrohydrodynamic atomization: A two-decade effort to produce and process micro-/nanoparticulate materials” Chem. Eng. Sci. (2015) 125:32-57. [cited by applicant]
Boda, et al., “Electrospraying an enabling technology for pharmaceutical and biomedical applications: A review” J. Aerosol. Sci. (2018) 125:164-181. [cited by applicant]
Zhou, et al., “Preparation and characterization of polycaprolactone microspheres by electrospraying” Aerosol Sci. Technol. (2016) 50(11):1201-1215. [cited by applicant]
Choi, et al., “Fabrication of Microbeads with a Controllable Hollow Interior and Porous Wall Using a Capillary Fluidic Device” Adv. Funct. Mater. (2009) 19(18):2943-2949. [cited by applicant]
Chang, et al., “Injectable scaffolds: Preparation and application in dental and craniofacial regeneration” Mater. Sci. Eng. R Rep. (2017) 111:1-26. [cited by applicant]
Ma, et al., “Hierarchical Nanofi brous Microspheres with Controlled Growth Factor Delivery for Bone Regeneration” Adv. Healthcare Mater. (2015) 4:2699-2708. [cited by applicant]
Chen, et al., “Electrospinning: An enabling nanotechnology platform for drug delivery and regenerative medicine” Adv Drug Deliv. Rev. (2018) 132:188-213. [cited by applicant]
Li, et al., “Therapeutic angiogenesis in ischemic muscles after local injection of fragmented fibers with loaded traditional Chinese medicine” Nanoscale (2015) 7(30):13075-87. [cited by applicant]